Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
Background Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognosticati...
Gespeichert in:
Veröffentlicht in: | Cytometry. Part B, Clinical cytometry Clinical cytometry, 2016-01, Vol.90 (1), p.26-30 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 30 |
---|---|
container_issue | 1 |
container_start_page | 26 |
container_title | Cytometry. Part B, Clinical cytometry |
container_volume | 90 |
creator | Stetler-Stevenson, Maryalice Paiva, Bruno Stoolman, Lloyd Lin, Pei Jorgensen, Jeffrey L. Orfao, Alberto Van Dongen, Jacques Rawstron, Andy C. |
description | Background
Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing.
Methods
A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached.
Results/Conclusion
The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society |
doi_str_mv | 10.1002/cyto.b.21249 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7511978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760895920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</originalsourceid><addsrcrecordid>eNqNkUtv1DAURi1ERR-wY40isWHRTP2I43iDBCMolaoWUKGCBZYTXw9uE3tqJ8D8ezxMOwIWiJWv5HOPPvtD6DHBM4IxPepWY5i1M0poJe-hPcI5LSvJxf3tXMldtJ_SFcaMV7V4gHYpl1gQTPfQl3nwCXyaUrGYnIHeeUiFDbEYVtCHQReD827QfREhOTPlwbgEOkGR9LDs8zHqTPhFob0pjB51obubySU3uuAfoh2r-wSPbs8D9OH1q4v5m_L0_Phk_uK07HiOV1oORrK66YjoLKdMSmobKoWoLCOdFQaAMtNoQSm2jWwJoUxXLa5Zg1klMDtAzzfe5dQOYDrwY9S9WsYcPa5U0E79eePdV7UI35TghEjRZMGzW0EMNxOkUQ0uddD32kOYkiKi4bSigvL_QGvcSC7pOtbTv9CrMEWffyJTXNQNZ3gtPNxQXQwpRbDb3ASrdcdq3bFq1a-OM_7k97du4btSM1BtgO-uh9U_ZWr-6eL85Z233Ky5NMKP7ZqO16oWTHB1eXasxMfP-N2leKves59Re8Nc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757685305</pqid></control><display><type>article</type><title>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>Stetler-Stevenson, Maryalice ; Paiva, Bruno ; Stoolman, Lloyd ; Lin, Pei ; Jorgensen, Jeffrey L. ; Orfao, Alberto ; Van Dongen, Jacques ; Rawstron, Andy C.</creator><creatorcontrib>Stetler-Stevenson, Maryalice ; Paiva, Bruno ; Stoolman, Lloyd ; Lin, Pei ; Jorgensen, Jeffrey L. ; Orfao, Alberto ; Van Dongen, Jacques ; Rawstron, Andy C.</creatorcontrib><description>Background
Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing.
Methods
A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached.
Results/Conclusion
The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society</description><identifier>ISSN: 1552-4949</identifier><identifier>EISSN: 1552-4957</identifier><identifier>DOI: 10.1002/cyto.b.21249</identifier><identifier>PMID: 25907102</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Antigens, CD - analysis ; Antigens, CD - genetics ; Antigens, CD - immunology ; Antineoplastic Agents - therapeutic use ; Data Accuracy ; flow cytometry ; Flow Cytometry - standards ; Humans ; Immunophenotyping - standards ; minimal residual disease ; Multiple Myeloma - diagnosis ; Multiple Myeloma - drug therapy ; Multiple Myeloma - genetics ; Multiple Myeloma - immunology ; myeloma ; Neoplasm, Residual - diagnosis ; Neoplasm, Residual - drug therapy ; Neoplasm, Residual - genetics ; Neoplasm, Residual - immunology ; Plasma Cells - drug effects ; Plasma Cells - pathology ; Prognosis ; Remission Induction ; Specimen Handling - standards ; Staining and Labeling - standards</subject><ispartof>Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.26-30</ispartof><rights>2015 International Clinical Cytometry Society</rights><rights>2015 International Clinical Cytometry Society.</rights><rights>2016 International Clinical Cytometry Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</citedby><cites>FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcyto.b.21249$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcyto.b.21249$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25907102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stetler-Stevenson, Maryalice</creatorcontrib><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Stoolman, Lloyd</creatorcontrib><creatorcontrib>Lin, Pei</creatorcontrib><creatorcontrib>Jorgensen, Jeffrey L.</creatorcontrib><creatorcontrib>Orfao, Alberto</creatorcontrib><creatorcontrib>Van Dongen, Jacques</creatorcontrib><creatorcontrib>Rawstron, Andy C.</creatorcontrib><title>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</title><title>Cytometry. Part B, Clinical cytometry</title><addtitle>Cytometry</addtitle><description>Background
Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing.
Methods
A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached.
Results/Conclusion
The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society</description><subject>Antigens, CD - analysis</subject><subject>Antigens, CD - genetics</subject><subject>Antigens, CD - immunology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Data Accuracy</subject><subject>flow cytometry</subject><subject>Flow Cytometry - standards</subject><subject>Humans</subject><subject>Immunophenotyping - standards</subject><subject>minimal residual disease</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - immunology</subject><subject>myeloma</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Neoplasm, Residual - drug therapy</subject><subject>Neoplasm, Residual - genetics</subject><subject>Neoplasm, Residual - immunology</subject><subject>Plasma Cells - drug effects</subject><subject>Plasma Cells - pathology</subject><subject>Prognosis</subject><subject>Remission Induction</subject><subject>Specimen Handling - standards</subject><subject>Staining and Labeling - standards</subject><issn>1552-4949</issn><issn>1552-4957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1DAURi1ERR-wY40isWHRTP2I43iDBCMolaoWUKGCBZYTXw9uE3tqJ8D8ezxMOwIWiJWv5HOPPvtD6DHBM4IxPepWY5i1M0poJe-hPcI5LSvJxf3tXMldtJ_SFcaMV7V4gHYpl1gQTPfQl3nwCXyaUrGYnIHeeUiFDbEYVtCHQReD827QfREhOTPlwbgEOkGR9LDs8zHqTPhFob0pjB51obubySU3uuAfoh2r-wSPbs8D9OH1q4v5m_L0_Phk_uK07HiOV1oORrK66YjoLKdMSmobKoWoLCOdFQaAMtNoQSm2jWwJoUxXLa5Zg1klMDtAzzfe5dQOYDrwY9S9WsYcPa5U0E79eePdV7UI35TghEjRZMGzW0EMNxOkUQ0uddD32kOYkiKi4bSigvL_QGvcSC7pOtbTv9CrMEWffyJTXNQNZ3gtPNxQXQwpRbDb3ASrdcdq3bFq1a-OM_7k97du4btSM1BtgO-uh9U_ZWr-6eL85Z233Ky5NMKP7ZqO16oWTHB1eXasxMfP-N2leKves59Re8Nc</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Stetler-Stevenson, Maryalice</creator><creator>Paiva, Bruno</creator><creator>Stoolman, Lloyd</creator><creator>Lin, Pei</creator><creator>Jorgensen, Jeffrey L.</creator><creator>Orfao, Alberto</creator><creator>Van Dongen, Jacques</creator><creator>Rawstron, Andy C.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201601</creationdate><title>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</title><author>Stetler-Stevenson, Maryalice ; Paiva, Bruno ; Stoolman, Lloyd ; Lin, Pei ; Jorgensen, Jeffrey L. ; Orfao, Alberto ; Van Dongen, Jacques ; Rawstron, Andy C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5949-f5ed9368c17cf523992f829774f31cf7dee23d8a7220f89b1123a4b0638034703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antigens, CD - analysis</topic><topic>Antigens, CD - genetics</topic><topic>Antigens, CD - immunology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Data Accuracy</topic><topic>flow cytometry</topic><topic>Flow Cytometry - standards</topic><topic>Humans</topic><topic>Immunophenotyping - standards</topic><topic>minimal residual disease</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - immunology</topic><topic>myeloma</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Neoplasm, Residual - drug therapy</topic><topic>Neoplasm, Residual - genetics</topic><topic>Neoplasm, Residual - immunology</topic><topic>Plasma Cells - drug effects</topic><topic>Plasma Cells - pathology</topic><topic>Prognosis</topic><topic>Remission Induction</topic><topic>Specimen Handling - standards</topic><topic>Staining and Labeling - standards</topic><toplevel>online_resources</toplevel><creatorcontrib>Stetler-Stevenson, Maryalice</creatorcontrib><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Stoolman, Lloyd</creatorcontrib><creatorcontrib>Lin, Pei</creatorcontrib><creatorcontrib>Jorgensen, Jeffrey L.</creatorcontrib><creatorcontrib>Orfao, Alberto</creatorcontrib><creatorcontrib>Van Dongen, Jacques</creatorcontrib><creatorcontrib>Rawstron, Andy C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cytometry. Part B, Clinical cytometry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stetler-Stevenson, Maryalice</au><au>Paiva, Bruno</au><au>Stoolman, Lloyd</au><au>Lin, Pei</au><au>Jorgensen, Jeffrey L.</au><au>Orfao, Alberto</au><au>Van Dongen, Jacques</au><au>Rawstron, Andy C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition</atitle><jtitle>Cytometry. Part B, Clinical cytometry</jtitle><addtitle>Cytometry</addtitle><date>2016-01</date><risdate>2016</risdate><volume>90</volume><issue>1</issue><spage>26</spage><epage>30</epage><pages>26-30</pages><issn>1552-4949</issn><eissn>1552-4957</eissn><abstract>Background
Flow cytometric (FC) detection of minimal residual disease (MRD) in multiple myeloma (MM) is prognostic and predictive of response to therapy. Therefore, standardization of FC MM MRD testing is vital to ensure better and uniform assessment of response to therapy and clinical prognostication. The International Clinical Cytometry Society and European Society for Clinical Cell Analysis, recognizing the need for standardized FC approaches, organized a working group to develop consensus guidelines on good clinical practice in FC MM MRD. Consensus guidelines are presented for specimen quality, staining process, reagent combinations, and the data acquisition process, all key factors in achieving high quality FC MM MRD testing.
Methods
A group of eight flow cytometrists currently performing FC testing in MM evaluated available literature on FC MM MRD testing. A document presenting best practice was developed and reviewed in successive rounds until consensus was reached.
Results/Conclusion
The consensus on best practice for detection of MRD in MM is that CD38, CD138, and CD45 are analyzed in combination with CD19, CD56, CD27, CD81, and CD117. Consensus guidelines on acceptable specimen quality, staining procedures, panel design, and data acquisition were developed. © 2015 International Clinical Cytometry Society</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25907102</pmid><doi>10.1002/cyto.b.21249</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1552-4949 |
ispartof | Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.26-30 |
issn | 1552-4949 1552-4957 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7511978 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Alma/SFX Local Collection |
subjects | Antigens, CD - analysis Antigens, CD - genetics Antigens, CD - immunology Antineoplastic Agents - therapeutic use Data Accuracy flow cytometry Flow Cytometry - standards Humans Immunophenotyping - standards minimal residual disease Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - immunology myeloma Neoplasm, Residual - diagnosis Neoplasm, Residual - drug therapy Neoplasm, Residual - genetics Neoplasm, Residual - immunology Plasma Cells - drug effects Plasma Cells - pathology Prognosis Remission Induction Specimen Handling - standards Staining and Labeling - standards |
title | Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Consensus%20guidelines%20for%20myeloma%20minimal%20residual%20disease%20sample%20staining%20and%20data%20acquisition&rft.jtitle=Cytometry.%20Part%20B,%20Clinical%20cytometry&rft.au=Stetler-Stevenson,%20Maryalice&rft.date=2016-01&rft.volume=90&rft.issue=1&rft.spage=26&rft.epage=30&rft.pages=26-30&rft.issn=1552-4949&rft.eissn=1552-4957&rft_id=info:doi/10.1002/cyto.b.21249&rft_dat=%3Cproquest_pubme%3E1760895920%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1757685305&rft_id=info:pmid/25907102&rfr_iscdi=true |